Literature DB >> 16307521

Proteomics of TGF-beta signaling and its impact on breast cancer.

Serhiy Souchelnytskyi1.   

Abstract

The complexity of mechanisms leading to the appearance and progression of cancer is a challenge being addressed by large-scale studies, such as proteomics. Simultaneous monitoring of thousands of proteins uncovers novel signaling mechanisms, thus revising our knowledge of tumorigenesis. Transforming growth factor (TGF)-beta is a secreted polypeptide that is known to inhibit tumor growth at the early stages of cancer, but promote metastasis at the later stages. Proteomics-based studies have significantly widened our knowledge of TGF-beta-dependent regulation of cell proliferation, apoptosis, DNA damage repair and transcription. This leads to better understanding of the TGF-beta role in human breast tumorigenesis, and opens the way for the development of novel anticancer treatments and drugs, with some of the drugs already entering clinics. This review discusses recent advances in proteomics studies of TGF-beta signaling and its contribution to the understanding and treatment of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16307521     DOI: 10.1586/14789450.2.6.925

Source DB:  PubMed          Journal:  Expert Rev Proteomics        ISSN: 1478-9450            Impact factor:   3.940


  3 in total

1.  Omics-based molecular target and biomarker identification.

Authors:  Zhang-Zhi Hu; Hongzhan Huang; Cathy H Wu; Mira Jung; Anatoly Dritschilo; Anna T Riegel; Anton Wellstein
Journal:  Methods Mol Biol       Date:  2011

Review 2.  Contribution of oncoproteomics to cancer biomarker discovery.

Authors:  William C S Cho
Journal:  Mol Cancer       Date:  2007-04-02       Impact factor: 27.401

3.  Differential Proteome Analysis Identifies TGF-β-Related Pro-Metastatic Proteins in a 4T1 Murine Breast Cancer Model.

Authors:  Misako Sato; Tsutomu Matsubara; Jun Adachi; Yuuki Hashimoto; Kazuna Fukamizu; Marina Kishida; Yu-An Yang; Lalage M Wakefield; Takeshi Tomonaga
Journal:  PLoS One       Date:  2015-05-18       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.